Activity of a Long-Acting Injectable Bedaquiline Formulation in a Paucibacillary Mouse Model of Latent Tuberculosis Infection
Amit Kaushik, Nicole C. Ammerman, Sandeep Tyagi, Vikram Saini, Iwan Vervoort, Sophie Lachau‐Durand, Eric L. Nuermberger, Koen Andries
Antimicrobial Agents and Chemotherapy · 2019-02
Abstract
The potent antituberculosis activity and long half-life of bedaquiline make it an attractive candidate for use in long-acting/extended-release formulations for the treatment of latent tuberculosis infection (LTBI). Our objective was to evaluate a long-acting injectable (LAI) bedaquiline formulation in a validated paucibacillary mouse model of LTBI.
MeSH terms
- Bedaquiline
- Medicine
- Regimen
- Tuberculosis
- Rifapentine
- Isoniazid
- Latent tuberculosis
- Dosing
- Lung
- Pharmacology
- Internal medicine
- Gastroenterology
- Mycobacterium tuberculosis